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Changes in the abundance of antennary fucosylated glycans in human total plasma
N-glycome (TPNG) have been associated with several diseases ranging from diabetes
to various forms of cancer. However, it is challenging to address this important part of
the human glycome. Most commonly, time-consuming chromatographic separations are
performed to differentially quantify core and antenna fucosylation. Obtaining sufficient
resolution for larger, more complex glycans can be challenging. We introduce a
matrix-assisted laser desorption/ionization—mass spectrometry (MALDI-MS) assay for
the relative quantitation of antennary fucosylation in TPNG. N-linked glycans are
released from plasma by PNGase F and further treated with a core fucosidase before
performing a linkage-informative sialic acid derivatization. The core fucosylated glycans
are thus depleted while the remaining antennary fucosylated glycans are quantitated.
Simultaneous quantitation of α2,3-linked sialic acids and antennary fucosylation allows
an estimation of the sialyl-Lewis x motif. The approach is feasible using either
ultrahigh-resolution Fourier-transform ion cyclotron resonance mass spectrometry or
time-of-flight mass spectrometry. The assay was used to investigate changes of
antennary fucosylation as clinically relevant marker in 14 colorectal cancer patients. In
accordance with a previous report, we found elevated levels of antennary fucosylation
pre-surgery which decreased after tumor resection. The assay has the potential for
revealing antennary fucosylation signatures in various conditions including diabetes and
different types of cancer.
Keywords: antennary fucose, glycomics, sialyl-Lewis x, MALDI-MS, FT-ICR-MS, CE-MS, colorectal cancer,
exoglycosidase
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INTRODUCTION
Changes in the relative abundance of either core or antennary
fucosylation have been associated with certain diseases or disease
states (Blomme et al., 2009; Testa et al., 2015). Here, we
focus on antennary fucosylation in human total plasma N-
glycome (TPNG) as a clinically relevant disease marker. For
instance, the abundance of antennary fucosylation in TPNG has
been correlated with (1) certain cancers such as hepatocellular
carcinoma (Benicky et al., 2014; Zhu et al., 2014), ovarian cancer
(Saldova et al., 2007) and colorectal cancer (Holst et al., 2016; de
Vroome et al., 2018; Doherty et al., 2018); (2) hepatocyte nuclear
factor 1 homeobox A—maturity-onset diabetes of the young
(HNF1A—MODY) (Thanabalasingham et al., 2013; Juszczak
et al., 2019); (3) inflammatory conditions (Brinkman-van der
Linden et al., 1998; Higai et al., 2005) and (4) with attention-
deficit hyperactivity disorder in children (Pivac et al., 2011).
These correlations have created a need for the development
of assays for quantitation of antennary fucosylation in TPNG.
Quantitation of changes in core fucosylated glycans will remain
relevant as well, but can better covered by existing approaches.
The quantitation of antennary fucosylation in TPNG was
also used for more specialized clinical purposes such as for
prognosis or for differentiating between closely related diseases.
For example, a lowered incidence of antennary fucosylation on
triantennary glycans was shown to discriminate HNF1A-MODY
patients from Type 1 and Type 2 diabetes (Thanabalasingham
et al., 2013). Current genetic tests for diagnosing HNF1A-MODY
are sometimes inconclusive, and there is a demand for additional
diagnostic markers (Schober et al., 2009; Thanabalasingham and
Owen, 2011; Hattersley and Patel, 2017). Plasma N-glycome
antennary fucosylation has been reported to be regulated by
HNF1A making it a proxy of HNF1A expression levels and
functions (Lauc et al., 2010). Hence, quantitation of antennary
fucosylation in TPNG has been found to be an HNF1A-MODY
disease biomarker with potential for complementing genetic tests
in disease diagnosis (Lauc et al., 2010; Thanabalasingham et al.,
2013). For colorectal cancer, both better diagnosis and prediction
of long-term survival are urgent clinical needs. Currently, long-
term survival predictions are mostly based on tumor node
metastasis classification which has low success rates (Cserni,
2003; de Vroome et al., 2018). This negatively affects the decision
making on therapy given to the patients. Antennary fucosylation
was shown to be associated with the recovery of colorectal cancer
patients after tumor resection (de Vroome et al., 2018), and thus
may have the potential for long-term survival prediction.
TPNG is a rich and convenient source of valuable associations
with diseases and disease states. It reflects the loss of systemic
or cellular homeostasis which may affect the regulation of
glycosylation pathways (Nairn et al., 2008; Blomme et al.,
2009; Lauc et al., 2010). Enabling a bird’s-eye view, TPNG
analysis is highly complementary to the target analysis of
specific proteins. Quantitation of low abundant antennary
fucosylated glycans in human TPNG is complicated by the
structural diversity of its component glycans. This diversity is
a combination of monosaccharide composition variants and
linkage isomers (Royle et al., 2008; Stumpo and Reinhold, 2010).
FIGURE 1 | Fucose epitopes on N-glycans in human plasma. [Blue square:
N-acetylglucosamine, green circle: mannose, yellow circle: galactose, red
triangle: fucose, pink diamond: N-acetylneuraminic acid (+45◦ α2,6-linked;
−45◦ α2,3-linked). For compositions see Figure 6].
Composed of diantennary, triantennary and tetraantennary N-
glycans, TPNG also features bisecting N-acetylglucosamine and
glycans with N-acetyllactosamine repeats, and complexity is
added by different levels of galactosylation, sialylation and
fucosylation (Stumpo and Reinhold, 2010; Vreeker et al., 2018;
Lageveen-Kammeijer et al., 2019). Fucosylation can be classified
as either core or antennary (Figure 1). Core fucosylation is
linked by an α(1-6) glycosidic bond to the reducing end N-
acetylglucosamine. Antennary fucosylation in TPNG mainly
features fucose residues that are linked by an α(1-3) glycosidic
bond (Lewis x epitope) to antennary N-acetylglucosamine
residues (Staudacher et al., 1999).
Methods for sample preparation and analysis of human TPNG
have been developed on a number of analytical platforms. This
includes liquid chromatography (LC)—fluorescence detection
(FLD) (Royle et al., 2008; Knezevic et al., 2011; Pivac et al.,
2011; Doherty et al., 2018), MALDI-MS (Reiding et al., 2014;
Bladergroen et al., 2015; Vreeker et al., 2018), and capillary
gel electrophoresis—laser-induced fluorescence (Ruhaak et al.,
2010; Vanderschaeghe et al., 2010). Each method has its
advantages and disadvantages when it comes to measuring
antennary fucosylation. Capillary gel electrophoresis—laser-
induced fluorescence (Vanderschaeghe et al., 2010) and LC-
FLD (Pivac et al., 2011; Doherty et al., 2018) are able
to resolve some antennary fucosylated glycans in TPNG
along their chromatographic dimension. However, LC-FLD
often requires extensive measurement time. Nonetheless, due
to its high precision and robustness, one of the most
attractive techniques for routine applications is LC-FLD.
MALDI-MS is gaining popularity in biomarker analysis since
it features short measurement time and high molecular
resolution. This, combined with linkage-informative sialic acid
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derivatization, is the ideal basis for an high throughput TPNG
glycomic assay in a research setting (Reiding et al., 2014;
Bladergroen et al., 2015; Vreeker et al., 2018). However, due
to identical mass, the differentiation between core fucosylation
and antennary fucosylation in monofucosylated glycans of the
same composition is not achieved by MALDI-MS. Therefore,
additional experiments are needed such as tandem mass
spectrometry (Chen and Flynn, 2007; Wuhrer et al., 2011;
Lattova et al., 2019) or exoglycosidase treatment (Royle et al.,
2008). Unfortunately, relative quantitation of fucose isomers by
tandem MS is hindered by the vastly different efficiencies of the
fragmentation pathways (Banazadeh et al., 2019; Lattova et al.,
2019). Additionally, potential fucose rearrangement influences
the ratios of diagnostic fragment ion(s), further interfering with
the assessment of mixtures by tandem MS (Harvey et al., 2002;
Chen and Flynn, 2007; Wuhrer et al., 2011). Alternatively,
endoglycosidases can be used for glycomic assays (Benicky
et al., 2014; Vanderschaeghe et al., 2018). For example, a
combination of Endo F2 and Endo F3 has been used to quantify
antennary fucosylation on diantennary and triantennary glycans
on hemopexin and complement factor H in patients suffering
from liver diseases (Benicky et al., 2014). However, until now,
this approach has not been demonstrated on TPNG. Due to the
narrow specificity of these endoglycosidases in contrast to the
vast structural diversity of TPNG, such an approach may not be
suitable for TPNG.
We developed an assay for the relative quantitation of
antennary fucosylation in human TPNG by combining MALDI-
MS and exoglycosidase approaches. It can be viewed as
complementing the existing approach for TPNG measurement
by MALDI-MS. The assay was applied to 14 colorectal cancer
patient samples. Consistent antennary fucosylation changes pre
vs. post tumor resection were detected which revealed the assays
potential for addressing biomedical research questions.
MATERIALS AND METHODS
Reagents and Samples
Disodium hydrogen phosphate dihydrate, potassium dihydrogen
phosphate, sodium chloride, 85% phosphoric acid, 30–33%
(v/v%) ammonium hydroxide, nonidet P-40 substitute (NP-
40), 1-hydroxybenzotriazole 97% (HOBt), ammonium acetate
and super-DHB (9:1 mixture of 2,5-dihydroxybenzoic acid
and 2-hydroxy-5-methoxybenzoic acid) were purchased from
Sigma Aldrich Chemie GmbH (Steinheim, Germany). 1-Ethyl-3-
[3-(dimethylamino)-propyl]carbodiimide hydrochloride (EDC)
was purchased from Fluorochem (Hadfield, UK). Analytical
grade ethanol, analytical grade glacial acetic acid, sodium dodecyl
sulfate (SDS), trifluoroacetic acid, and potassium hydroxide were
purchased from Merck KGaA (Darmstadt, Germany). HPLC-
grade acetonitrile was purchased from Biosolve (Valkenswaard,
The Netherlands). Girard’s Reagent P (GiRP) was purchased
from TCI Development Co. Ltd. (Tokyo, Japan). 5× phosphate
buffered saline solution (PBS; 175mM; pH 7.3) was prepared
by dissolving 285 g of disodium hydrogen phosphate dihydrate,
23.8 g of potassium dihydrogen phosphate and 425 g of sodium
chloride in 10 L deionized water. The 5× acidic PBS was prepared
by adding 68 µL of 85% phosphoric acid (14.7M) to 9.93mL of
the 5× PBS. Recombinant Peptide N-glycosidase F (PNGase F)
was obtained from Roche Diagnostics (Mannheim, Germany).
The recombinant core fucosidase, commercially known as α1-
2,4,6 Fucosidase O, was purchased from New England BioLabs
(MA, USA). However, activity on the α1,4-linkage is reported
as very low. Under the employed conditions, the enzyme did
not noticeably act on antennary fucoses present in TPNG (see
section Result and Discussion). Peptide Calibration Standard II
was purchased from Bruker Daltonic (Bremen, Germany).
Human plasma standard (Visucon-F frozen normal control
plasma, pooled from a minimum of 20 human donors,
citrated and buffered in 0.02M 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) was purchased from Affinity
Biologicals (Ancaster, Ontario, Canada).
The pre-operative vs. 45 days post-operative pairs of 14
colorectal cancer patient samples were collected as part of a
biobank as was previously described (de Vroome et al., 2018).
These serum samples were collected between October 2002
and March 2013 by the Leiden University Medical Center
Surgical Oncology Biobank. This study was approved by the
Medical Ethics Committee of the Leiden University Medical
Center and was performed in accordance with the Code of
Conduct of the Federation of Medical Scientific Societies in the
Netherlands (http://www.federa.org/).
N-Glycan Release
PNGase F release of human TPNG was performed similarly as
previously described (Vreeker et al., 2018). Briefly, 4µL of plasma
was added to 8 µL of 2% SDS in a polypropylene 96 well V-
bottom plate (V-96 microwell, NUNC, Roskilde, Denmark). The
plate was sealed (adhesive plate seals, Thermo Scientific, UK) and
mildly shaken on a plate shaker for 5min, before incubating at
60◦C for 10min. Additionally, 8 µL of the PNGase F releasing
mixture (4 µL of 4% NP-40 solution, 4 µL of 5× acidic PBS and
0.4 µL of PNGase F) was then added to the plasma samples. The
plate was sealed and mildly shaken on a plate shaker for 5min
before incubating overnight (15–18 h) at 37◦C.
Depletion of Core Fucosylation
The overnight incubated plasma release mixture (5 µL) was
diluted with 45 µL of 1× acidic PBS solution in a 96 well
V-bottom plate (V-96 microwell, Grenier Bio-one, Germany).
The plate was mildly shaken on a plate shaker for 5min,
before transferring 1–2 µL of core fucosidase mixture (0.65 µL
deionized water, 0.75 µL of 4% NP-40 solution, 0.4 µL of 5×
acidic PBS and 0.2 µL/0.4 Units of core fucosidase) in a 96
well V-bottom plate. After sealing of the plate, the samples were
incubated overnight (15–18 h) at 37◦C in an enclosed, humidified
chamber to prevent evaporation.
Linkage Specific Sialic Acid Derivatization
Sialic acid derivatization was performed as previously described
(Lageveen-Kammeijer et al., 2019), but with minor alterations.
With this approach, the carboxylic acid groups of α(2,6)-linked
sialic acids are ethyl esterified while the α(2,3)-linked sialic
acids are amidated. Briefly, 60 µL of ethyl esterification reagent
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(solution of 0.25M EDC and 0.25M HOBt in ethanol) was
added to the core defucosylated samples. The plate was sealed
and incubated at 37◦C for 30min. Twelve microliters of 30–
33% (v/v%) NH4OH solution were added to the wells and the
sealed plate incubated for another 30min at 37◦C. Seventy-
two microliters of acetonitrile was added to the wells, after
which cotton hydrophilic interaction liquid chromatography
(HILIC)—solid-phase extraction (SPE) microtip purification was
performed immediately.
Cotton Hydrophilic Interaction Liquid
Chromatography—Solid-Phase Extraction
Microtip Purification
This purification step was performed as previously described
(Selman et al., 2011) with minor modifications. The cotton
HILIC-SPE microtips were prepared by inserting a cotton strand
of length 3–4mm into a 20 µL capacity microtip (Mettier-
Toledo, Switzerland) and pushing it into place with a stream
of pressurized air/nitrogen. Conditioning was performed by
pipetting 5 times 20µL of water, followed by an equilibration step
of pipetting 3 times 20 µL of 85% acetonitrile. The derivatized
samples were loaded onto the HILIC-SPE by pipetting 20 µL
of it 20 times. Washing was performed with 3 times 20 µL of
85% acetonitrile containing 1% trifluoroacetic acid and 3 times
20 µL of 85% acetonitrile, consecutively. The glycans were eluted
from the HILIC-SPE by repeatedly, 10 times, pipetting 4 µL of
deionized water in a 96 well V-bottom plate (V-96 microwell,
Grenier Bio-one, Germany). All steps were performed with a 12
channel multi-channel pipette.
Purified glycan samples (1 µL) were spotted on an MTP
anchor chip 600/384 TF MALDI target plate (Bruker Daltonics,
Bremen, Germany), followed by the addition of 1 µL of the
MALDI matrix solution (50% acetonitrile solution of 2.5 mg/mL
super-DHB and 0.1mM sodium hydroxide). The solutions were
mixed on the plate with a pipette. The spotted samples were
allowed to air dry before performing MALDI- time-of-flight -MS
(MALDI-TOF-MS) or MALDI- Fourier-transform ion cyclotron
resonance -MS (MALDI-FT-ICR-MS) measurements.
MALDI-TOF-MS Analysis
The analysis was performed on an UltrafleXtreme Mass
spectrometer in reflectron positive ion mode (Bruker Daltonics,
Bremen, Germany) which was operated by FlexControl version
3.4 (Build 135). A Bruker Smartbeam-II laser was used for
ionization at an irradiation frequency of 1 kHz using the
“small” predefined laser shot pattern. Each sample spot was
irradiated by 20,000 shots with 200 shots at each laser raster.
Irradiation was performed randomly over the complete sample
spot. Spectra were recorded within an m/z range of 900–5,000.
Samples were measured in an automated manner using the
AutoXecute function of FlexControl. Before each measurement,
the instrument was calibrated with a peptide standard mix
(Peptide Calibration Standard II, Bruker Daltonics).
MALDI-FT-ICR-MS Analysis
The analysis was performed in positive ion mode on a Bruker
15T solariX XR FT-ICR mass spectrometer equipped with a
CombiSource and a ParaCell (Bruker Daltonics). The system was
operated by ftmsControl version 2.2.0 (Build 150). A Bruker
Smartbeam- II laser was used for ionization at an irradiation
frequency of 500Hz using the “medium” predefined laser shot
pattern. Each sample spot was irradiated with a raster of 200
laser shots. Ten such scans were performed randomly over the
complete sample spot. Spectra were acquired within an m/z-
range 1,011–5,000 with 1 million data points (transient time
2.3069 s). Samples were measured in an automated manner using
the AutoXecute function of ftmsControl.
Processing of MALDI-MS Data
The MALDI-TOF-MS spectra were internally calibrated using
FlexAnalysis version 3.4 (Build 76; Bruker Daltonic). The glycan
calibrants used were [H3N4 + Na]+ of m/z 1,339.476, [H5N4
+ Na]+ of m/z 1,663.581, [H5N4E1 + Na]+ of m/z 1,982.708,
[H5N4E2 + Na]+ of m/z 2,301.835, [H5N5E2 + Na]+ of
m/z 2,504.914, [H6N5E2Am1 + Na]+ of m/z 2,957.078 and
[H7N6E2Am2 + Na]+ of m/z 3,612.322. The.xy files generated
by Flexanalysis were further processed with Massy Tools (Jansen
et al., 2015). A second round of internal spectral calibration was
performed with at least four calibrants in the low m/z range and
at least three calibrants in the medium m/z range, having to pass
signal to noise ratio (S/N) at least above 15. The m/z window
for calibration, peak detection, and spectral data integration was
taken at ± 0.45 Th. The background detection windows were set
to 20 Th.
The MALDI-FT-ICR-MS spectra were acquired in serial
mode. Thus, a single combined file was generated. This file was
split into individual compound spectra and transformed into.xy
files using DataAnalysis version 5 (Bruker Daltonics). Calibration
of these spectra was performed in Massy Tools, for which at
least four calibrants in the low m/z range and at least three
calibrants in the medium m/z range, have to pass S/N at least
above 50. The m/z window for calibration was taken at ± 0.10
Th. Peak detection and spectral data integration was performed
using an extraction window depending on the defined glycans in
the analyte list. This was done so as to exclude interferences in the
spectra. The background detection windows were set at the value
of 20 Th.
The calibrant list and analyte list for MALDI-TOF-
MS spectra and MALDI-FT-ICR-MS spectra are shown
in Supplementary Tables S1, S2, respectively. The table
of all identified and quantitated glycans by MALDI-FT-
ICR-MS and MALDI-TOF-MS, respectively, are shown in
Supplementary Table S3. At least 85% of the theoretical isotopic
distribution of each glycan analyte was integrated. The Massy
tools output was used further for analyte curation, which was
based on multiple criteria. These were S/N ≥ 9, isotopic pattern
quality ≤ 0.25 and mass accuracy between ± 20 ppm (MALDI-
TOF-MS) or± 10 ppm (MALDI-FT-ICR-MS). Spectra for which
the number of glycan analytes passing these criteria were <50%
of the total number of defined glycans in the analyte list, were not
considered for further processing as these spectra were deemed
of low quality. The absolute area of the curated glycans was
corrected to 100% of their respective isotopic distribution, before
using them in total area normalization.
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Derived traits, focusing on features rather than individual
glycans, were calculated from the relative areas of the
glycan compositions using an in-house prepared R script
(Supplementary Table S4). Statistical significance of the
differences between pre-operative vs. post-operative colorectal
cancer patient samples was assessed by a Wilcoxon matched-
pairs signed-rank test with α = 0.05. Multiple-testing correction
was performed using a false discovery rate of 1% calculated
with the Benjamini and Hochberg method. These statistical tests
were performed in GraphPad Prism version 8.0.1. The box and
whisker plots used for representing the features were made by an
in-house prepared R script.
Method Optimization and Assay
Performance
All optimization experiments of the assay were measured
on the MALDI-TOF-MS (Supplementary Material “Assay
optimization”). Data processing for these mentioned
optimization experiments was done using the mass list
of the negative control (fucosidase untreated TPNG)
(Supplementary Table S2). Quantitation of residual core
fucosylated glycans allowed the assessment of the completeness
of the core defucosylation. Importantly, all identified antennary
fucosylated glycans were also included in the mass list of the
negative control (fucosidase untreated TPNG).
The intermediate precision of the antennary fucose assay
for combined sample preparation and measurements on the
MALDI-TOF-MS or MALDI-FT-ICR-MS were performed in
three independent experiments on three different days within a
period of 5 days. For each of these experiments, the assay was
performed with nine replicates of glycan releases from a human
plasma pool (Visucon-F, Affinity Biologicals). Data processing




Identification of core fucosylated glycans, antennary fucosylated
glycans, and composition containing both isomers was done
by comparing the MALDI-FT-ICR-MS spectra from the assay
(core fucosidase treated) to the negative control (fucosidase
untreated). The identified antennary fucosylated glycans and
mixed fucosylated isomeric glycans were structurally confirmed
by targeted collision induced dissociation (CID) fragmentation
on a capillary electrophoresis—electrospray ionization–tandem
MS (CE-ESI-MS/MS) platform. The samples were performed in
12 replicates of which nine were used for MALDI-FT-ICR-MS
measurements while the remaining three were used for CE-ESI-
MS/MS measurements (n= 3).
For the CE-ESI-MS/MS measurement, the replicates from
the assay and the negative controls were, respectively, pooled
together and dried down in a vacuumed centrifuge (Salm en
Kipp, Breukelen, Netherlands) at 50◦C. They were used for
permanent cationic labeling with GiRP as previously described
(Lageveen-Kammeijer et al., 2019) but with certain alterations.
Briefly, 10 µL of GiRP labeling solution (7.5mg GiRP dissolved
in a solution of 720 µL ethanol and 80 µL glacial acetic acid)
was added to the dried samples. The plate was sealed and mildly
shaken on a plate shaker for 5min before incubating at 60◦C
for 1 h. After incubation, the samples were dried down in a
vacuumed centrifuge at 50◦C and then re-suspended in 5 µL
of deionized water. In total, 3.6 µL of the GiRP labeled glycans
were mixed with 2.4 µL of 250mM ammonium acetate solution
as leading electrolytes (250mM ammonium acetate solution
adjusted to pH 4 with glacial acetic acid) before being transferred
into a vial (nanoVial, Sciex, Framingham, USA).
All CE-ESI-MS/MS analyses were performed on a static coated
neutral capillary cartridge (Neutral OptiMS cartridge, Sciex),
fitted into a CESI 8000 system (Sciex). The CE system was
coupled with an Impact HD UHR-QTOF-MS system (Bruker
Daltonics). When the capillary was not in use, a continuous flow
of water at 10 psi was applied to the separation line. Prior to
usage, the separation line and reverse line were filled with the
background electrolyte containing 10% acetic acid (sonicated in
a water bath for 10min). Prior to sample injection, the separation
line was flushed with 0.1MHCl at a pressure of 100 psi for 5min.
This was followed by flushing the reverse line with background
electrolyte at 75 psi for 3min. The separation line was filled
with background electrolyte by applying a pressure of 100 psi
for 10min. The sample was injected into the separation line of
the capillary from the nanovials via a hydrodynamic injection
of 12.5 psi for 24 s (about 5% of the capillary volume). The
tip of the separation line was washed by momentary dipping
it into a vial of background electrolyte, followed by injecting a
background electrolyte plug with a pressure of 2.5 psi for 15 s.
A 20 kV voltage of normal polarity (cathode toward the end of
the capillary) was applied on the capillary for 30min. During this
step, a continuous flow of 2 psi was applied only on the reverse
line. After 30min, a flow of background electrolyte is applied to
both the separation line and reverse line by applying a pressure
of 2 psi on both lines for 40min. Finally, the voltage on the
capillary was ramped down over 5min to 1 kV before termination
of the run. The capillary was maintained at 30◦C throughout
the analysis.
For the MS analysis, a dopant enriched nitrogen gas
(acetonitrile as dopant) at 0.2 bar was used for nebulization at
the ESI captive sprayer. The drying gas of nitrogen at 150◦C was
introduced at the source at 1.2 L/min and the internal capillary of
theMS was maintained at 1,200V. A targeted CID fragmentation
was performed on 20 glycan analytes of interested. This list was
divided into two inclusion lists on the software otof control
version 3.4 (Build 14; Bruker Daltonics) which was used for
operating the MS and MS/MS analysis. Hence each sample was
measured twice in-order to fragment all the glycan analytes of
interest. The MS/MS fragmentation spectra were collected at a
rate of 1Hz within anm/z-range of 150–2,000 and at an absolute
intensity threshold at 2,274 on the m/z values of interest. The
targeted precursor ions were isolated with a width of 8–15 Th
depending on the m/z values. The collision energies of the CID
cell was set in an m/z dependent manner, ranging from 35 eV
for singly charged precursor ions of m/z 500 to 70 eV for singly
charged precursor ions atm/z 2,000. Data analysis was done using
DataAnalysis version 5 (Bruker Daltonics).
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Hydrophilic Interaction Liquid
Chromatography Analysis
PNGase F released N-glycans from 12 replicates of human
plasma samples (Visucon-F) were used for procainamide labeling
and analysis on a HILIC-FLD-MSn platform as previously
described (Kozak et al., 2015). Following PNGase F treatment, 8
µL of each sample was dried down and the released N-glycans
converted to aldoses with 0.1% formic acid, filtered through a
protein binding plate (LC-PBM-96, Ludger, Oxford, UK), washed
twice with 100 µL of water and dried. N-glycans were labeled by
reductive amination in 10 µL of water and 10 µL procainamide
labeling solution (LT-KPROC-24 containing NaCNBH3, Ludger)
and incubated at 65◦C for 1 h. A HILIC-type clean-up plate (LC-
PROC-96, Ludger) was used to remove unreacted procainamide
dye. Procainamide labeled N-glycans were eluted in 300 µL of
water. The samples were dried and resuspended in water (50 µL)
for further analysis.
Procainamide-labeled samples were analyzed by HILIC-FLD-
MSn. 12.5 µL of each sample was injected into an ACQUITY
BEH Glycan column (1.7µm, 2.1 × 150mm) at 40◦C on a
Dionex Ultimate 3000 UHPLC instrument with a fluorescence
detector (ex= 310 nm and em= 370 nm attached to an Amazon
Speed ETD (Bruker Daltonics). The running conditions used
were as follows: solvent A was 50mM ammonium formate (pH
4.4) (LS-NBUFFX40, Ludger), and solvent B was acetonitrile.
Gradient conditions were as follows: 0–53.5min, 76–51% B,
0.4 mL/min; 53.5–55.5min, 51–0% B, 0.4–0.2 mL/min; 55.5–
57.5min, 0% B at a flow rate of 0.2 mL/min; 57.5–59.5min,
0–76% B, 0.2 mL/min; 59.5–65.5min, 76% B, 0.2 mL/min;
65.5–66.5min, 76% B, 0.2–0.4 mL/min; 66.5–70.0min, 76%
B, 0.4 mL/min. The Amazon Speed settings used were as
follows: source temperature, 250◦C; gas flow, 10 L/min; capillary
voltage, 4,500V; ICC target, 200,000; Max. accu. time (Maximum
Accumulation Time), 50.00ms; rolling average, 2; number of
precursor ions selected, 3; release after 0.2min; positive ion
mode; scan mode, enhanced resolution; mass range scanned,
400–1,500; target mass, 900.
RESULTS AND DISCUSSIONS
The workflow for the antennary fucose assay is shown in
Figure 2. Released N-glycans from human plasma were treated
with an α1,6-linkage-selective fucosidase (core fucosidase) to
deplete core fucosylation. Antennary fucosylation remained and
was relatively quantified by MALDI-FT-ICR-MS or MALDI-
TOF-MS. Information on sialic linkage is obtained in parallel,
potentially improving the estimation of sialyl-Lewis x abundance.
An overview of all analytical methods used during the
development of the assay is shown in Supplementary Figure S1.
Human TPNG was 28.3% ± 0.5% fucosylated. Most of
this is core fucosylation (Supplementary Table S5). Hence,
it was important to optimize the assay with a focus on a
robust and complete depletion of core fucosylation of TPNG.
This aids a robust relative quantitation of the remaining
antennary fucosylated glycans by MALDI-MS. The efficient
use of costly reagents, specifically the core fucosidase, was
also addressed. During the optimization steps, completeness
of core defucosylation was judged by the inability to quantify
by MALDI-MS (signal to noise ratio (S/N) < 9) some of the
most abundant core fucosylated glycans namely [H3N4F1 +
Na]+ of m/z 1,485.53 and [H4N4F1 + Na]+ of m/z 1,647.59
(Supplementary Figure S4). Details pertaining to assay
optimization are described in the Supplementary Material
section “Assay optimization.” For these optimized assay
conditions, a complete core defucosylation of TPNG could
already be achieved with 0.2 units of core fucosidase (Figure 3).
However, to facilitate robustness of the core defucosylation
a 2-fold greater amount (0.4 units) was chosen for further
experiments. Equally important is the preservation of antennary
fucosylation. A fucosidase specific, or at least highly selective,
for the α1,6-linkage over other linkages significant in TPNG
(mainly α1,3-linkage) is therefore essential. The MS/MS spectra
provided in the Supplementary Material demonstrate that
core fucoses are removed while antennary fucoses remain
(see also following sub-section) with the chosen enzyme.
The integrity of the antennary fucosylation under increased
enzyme concentrations (Figure 3) and incubation times (data
not shown) further supports the α1,6-linkage selectivity.
An absence of the oxonium ion of m/z 658.26 [galactose—
N-acetylglucosamine(fucose)2+H]
+ excluded a significant
presence of Lewis y or Lewis b structures.
Identification of Antennary Fucosylated
Glycans in Total Plasma N-Glycome
Core fucosylated glycans and antennary fucosylated glycans in
TPNG were identified by comparing the TPNG profile with
and without core fucosidase treatment (Figure 4). A more
detailed view can be found in Supplementary Figures S2, S3
FIGURE 2 | Workflow of the antennary fucose assay for human plasma.
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FIGURE 3 | Residual core fucosylation on TPNG after incubation with varying amounts of core fucosidase. The amounts of core fucosylation on complex N-glycans
were calculated and were normalized to their lowest and highest mean values. Error bars show the standard deviation of the mean of three replicates.
for MALDI-FT-ICR-MS and MALDI-TOF-MS spectra,
respectively. Interestingly, some monofucosylated glycan
compositions in TPNG showed a mixture of both core and
antennary fucosylated isomers (Supplementary Figure S4).
CID spectra, obtained on a CE-ESI-MS/MS platform, provided
an orthogonal layer of evidence (Figure 5). CID spectra for
all identified antennary fucosylated glycans are shown in
Supplementary Figures S5–S24. Antennary fucosylation was
identified by the formation of the diagnostic B-ion ofm/z 512.198
assigned as [galactose-N-acetylglucosamine(fucose)+H]+
(Wuhrer et al., 2011). Core fucosylation was identified by
the formation of the Y-ion of m/z 501.219 assigned as [N-
acetylglucosamine(fucose)-GiRP]+. Core fucosylation also
generates, to a lesser extent, the B-ion of m/z 512.198 assigned
as [mannose-N-acetylglucosamine(fucose)+H]+ caused by
fucose rearrangement (Harvey et al., 2002; Chen and Flynn,
2007; Wuhrer et al., 2011; Lettow et al., 2019). This complicates
the assessment of mixtures, especially relative quantitation
by MS/MS. Although, fucose rearrangement also limits the
sensitivity of antennary fucose identification in the presence
of core fucose isomers, significant contributions of antennary
fucose are still readily identified (Figure 5).
Notably, no core fucosylation remained after core
fucosidase treatment. This was assessed by the absence of
the core fucosylated glycans H3N4F1and H4N4F1 (S/N < 9)
(Supplementary Figure S25). As expected the corresponding
afucosylated glycoforms increased in abundance (Figure 4).
The remaining fucosylated glycans are suggested to be solely
antennary fucosylated.
As similar relative abundances were maintained after
core fucosidase treatment, the species, H6N5F2Am2E1,
H6N5F1Am1E2, H7N6F1Am1E1, H7N6F1Am2E1,
H7N6F1Am1E2, H7N6F1Am3E1, H7N6F2Am3E1,
H7N6F1Am2E2, H7N6F2Am2E2, and H7N6F1Am1E3, are
assigned as antennary fucosylated in human TPNG. This was
confirmed by MS/MS (Supplementary Figures S14–S23).
Interestingly, we were able to prove that the difucosylated
glycans, H6N5F2Am2E1, H7N6F2Am3E1, and H7N6F2Am2E2,
contained only antennary fucosylation and no core fucosylation.
Previously, these glycans have often been assigned as containing
one core and one antennary fucose (Vreeker et al., 2018). In
fact, we were unable to identify any multifucosylated glycan
compositions in TPNG having both core and antennary
fucose residues on the same glycan. However, at low
abundances (<0.5%), two such mixed, multifucosylated
glycans, H6N5F2Am2E1 and H6N5F2Am1E2, have been
convincingly demonstrated (Lageveen-Kammeijer et al., 2019).
On haptoglobin, multifucosylated glycans having both core and
antennary residues were shown to have clinical relevance in
subtyping hepatocellular carcinoma patients (Zhu et al., 2014).
Thus, it may be very important to differentiate between glycans
with multiple antennary fucoses and glycans containing both
a core and an antennary fucose. The former may be directly
assessed with our assay, the latter indirectly, either via an increase
of the resulting monofucosylated species or by comparison to
the negative control (fucosidase untreated).
A range of monofucosylated compositions were found to
be a mixture of core fucosylated and antennary fucosylated
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FIGURE 4 | Identification of core fucosylated glycans and antennary fucosylated glycans by exoglycosidase and MALDI-FT-ICR-MS. The TPNG profile without core
fucosidase treatment was compared to the profile after treatment, within (A) the m/z range of 1,200–3,200 and (B) the m/z range of 3,120–4,200. Core fucosylated
glycans [red m/z values] are converted to their corresponding afucosylated glycans [purple m/z values], upon core fucosidase treatment. Only the antennary
fucosylated glycans [blue m/z values] and the antennary fucose isomers of the mixed fucose isomeric (core or antennary fucosylation) glycans [green m/z values]
remain after core fucosidase treatment. All m/z values of annotated glycans belong to [M + Na]+ ions. The description of the glycan cartoons are shown in Figure 1.
isomers, including for the following glycan compositions:
H5N5F1, H5N4F1E1, H5N5F1E1, H5N4F1Am1E1, H5N4F1E2,
H5N5F1E2, H6N5F1Am1E1, H6N5F1E2, and H6N5F1Am2E1.
Their relative abundances were significantly lowered, but
signals did not disappear after core fucosidase treatment
(Supplementary Figure S4 and Supplementary Table S4).
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FIGURE 5 | CE-ESI-MS/MS spectra of sialic acid derivatized and GiRP labeled TPNG for the confirmation of antennary, mixed isomeric (core or antennary
fucosylation) and core fucosylated glycans. (A) The [M+H]2+ ion of H4N4F1 (m/z 879.838) is fragmented for fucosidase untreated TPNG. Its fragment ions are
indicative of core fucosylation. (B) The [M+2H]3+ ion of H6N5F1E2 (m/z 975.709) [second isotope] is fragmented for fucosidase untreated TPNG. Its fragment ions
are indicative of both core fucosylated and antennary fucosylated isomers. (C) The ion [M+2H]3+ of H6N5F1E2 (m/z 975.709) [second isotope] is again fragmented,
but for core fucosidase treated TPNG. Its fragmentation pattern is indicative of only antennary fucosylation. The descriptions of the glycan cartoons are shown in
Figure 1. GiRP represents Girard’s reagent P label; * represents an oxonium ion.
These findings were further supported by their MS/MS spectra
(Supplementary Figures S5–S13). As a representative example,
the MS/MS fragmentation of the monofucosylated composition
H6N5F1E2 is shown without and with core defucosylation in
Figures 5B,C, respectively. Fragmentation of this glycan from
untreated human TPNG resulted in the formation of similar
abundances of both a Y-ion of m/z 501.219 and a B-ion of m/z
512.198. This is typical of a mixture of core and antennary
fucosylation (Figure 5B). Expectedly, the fragmentation of this
glycan after core defucosylation, results in the formation of only
the B-ion of m/z 512.198 which is indicative of only antennary
fucosylation (Figure 5C). Thus, H6N5F1E2 in human TPNG is
comprised of a mixture of core fucose isomers and antennary
fucose isomers. Such monofucosylated glycan compositions
which include mixtures of core fucose and antennary fucose
isomers contribute to a total abundance of 12.1% ± 1.0% in
human TPNG. Our assay determined 3.1%± 0.3% of them to be
antennary fucosylated (Supplementary Table S5).
A B-ion of m/z 831.325 was observed in several CID
spectra which was tentatively assigned as [N-acetylneuraminic
acid(amidated)-N-acetylglucosamine(fucose)+H]+. This is an
unconventional motif, because antenna fucosylation is generally
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observed on α2-3 sialylated antennae. The ion may be caused
by fucose rearrangement between the antennae (Wuhrer et al.,
2011). For the composition H6N5F1E2 (Figure 5C), the higher
abundance of the B-ion of m/z 512.198 compared to m/z
831.325, indeed indicates a Lewis x structure to be more likely.
Additionally, for the compositions with only α2-6 sialylated
antennae, H5N4F1E2 and H5N5F1E2, we did not observe a
B-ion of m/z 831.325 but rather the Y-ion of m/z 501.219
(Supplementary Figures S9B, S10B). Thus, these compositions
are partly explained by incomplete core defucosylation. Their
antennary fucosylated portion, suggested by the significant
abundance of the Y-ion of m/z 512.198, could be due to side-
products of the esterification of α(2-3) linked sialic acids (Toyoda
et al., 2008; Pongracz et al., 2019; Suzuki et al., 2019).
After core fucosidase treatment, H6N5F2Am2E1
and H7N6F1Am1E2 showed a lower abundance
(Supplementary Table S6). However, from the MS/MS spectra
without fucosidase treatment, core fucosylation could not
be confirmed on these glycans due to the lack of the Y-
ion of m/z 501.219 (Supplementary Figures S16A, S18A).
H6N5F2Am2E1 and H7N6F2Am2E1 both contribute to
<0.25% to TPNG, and the ratio of their abundances for core
fucosidase treated / untreated is 0.83 and 0.88, respectively
(Supplementary Table S5). Thus, if their core fucosylated
isomers are present in TPNG, they might be too low abundant
(≤0.03%) to be identified in MS/MS spectra of our CE-
ESI-MS/MS platform. Furthermore, a complete depletion
of core fucosylation for H5N5F1, H5N4F1E1, H5N5F1E1,
H5N4F1E2, and H5N5F1E2 was not achieved as the Y-ion of
m/z 501.219 was still observed in their MS/MS spectra, although
the B-ion of m/z 512.198 is equally, if not more abundant
(Supplementary Figures S5–S7, S9, S10). However, most of the
core fucosylation was removed (Supplementary Figure S4). Due
to the relatively low abundance of the affected glycans, this small
overestimation is not likely to have a significant impact on the
measurements. A pessimistic estimate is an 0.1% bias in relative
quantitation of total antennary fucosylation (<3% for affected
glycans, such as H5N4F1E1).
Assay Performance
Intermediate precision was assessed by three independent
experiments on different days each with nine replicates
of glycan releases from a human plasma pool measured
by MALDI-FT-ICR-MS. Seventy glycans were quantified
(Supplementary Table S7, Supplementary Figure S26), which
included 19 antennary fucosylated glycans (Figure 6). These
antennary fucosylated glycans make up 11.8% ± 0.9% of
total abundance in human TPNG, with the three most
abundant antennary fucosylated glycans, H6N5F1Am1E2,
H5N4F1Am1E1, and H6N5F1Am2E1, contributing 6.80%
± 0.63%, 0.84% ± 0.03% and 0.66% ± 0.06%, respectively
(Figure 6B). The abundance of H6N5F1Am1E2 is consistent
with previous quantitation using MALDI-FT-ICR-MS (Vreeker
et al., 2018). The median of intermediate precisions for the 19
quantitated antennary fucosylated glycans is 12.4% (9.1–18.5%
interquartile range; Supplementary Figure S27), which is in-line
with the ca. 10% previously described for MALDI-FT-ICR-MS
analysis of all TPNG glycans (Vreeker et al., 2018). Notably,
neither the focus on low abundant antennary fucosylated glycans
(<1%, except H6N5F1Am1E2) nor the additional processing
steps resulted in a marked loss of precision.
Previous research quantified 21 antennary fucosylated glycans
in human TPNG using a MALDI-FT-ICR-MS platform (Vreeker
et al., 2018). These antennary fucosylated glycans are consistent
with our findings. However, we were also able to identify a
mixture of both core fucose isomers and antennary fucose
isomers for nine of these monofucosylated glycan compositions
(Supplementary Figure S4). For example, we have identified
H6N5F1E2 and H5N4F1Am1E1 as being a mixture of core
fucose isomers and antennary fucose isomers. Previously, these
glycans were assumed to be antennary fucosylated (H6N5F1E2)
and core fucosylated (H5N4F1Am1E1), respectively. The specific
measurement of antennary fucosylated glycans using our assay
may increase the accuracy of the relative quantitation of
antennary fucose.
To demonstrate the accuracy of the quantitation of antennary
fucosylated glycans, procainamide labeled human TPNG was
analyzed on a HILIC-FLD-MSn platform (Kozak et al., 2015).
This analytical platformwas chosen for its accuracy and precision
of measurements. Antennary fucosylated glycan peaks were
identified from their CID spectra while relative quantitation was
performed from the FLD chromatograms. By using the FLD
chromatogram instead of the MS spectra for quantification, we
overcome the ionization bias resulting from charge differences
conferred by underivatized sialic acids (which applies to most
antennary fucosylated glycans), as compared to the neutral
glycans (Wheeler et al., 2009). As the HILIC-FLD-MSn platform
did not identify antennary fucosylated tetraantennary glycans, we
based the comparison to our MALDI-MS method on antennary
fucosylation of triantennary glycans only. This includes nearly
70% of the total abundance of antennary fucosylated glycans
in TPNG (Supplementary Table S7). With 32.4 ± 1.1% result
from our MALDI-MS method were highly comparable results to
the 34.7 ± 1.3% quantified with the HILIC-FLD-MSn reference
method. Thus, our assay is capable of accurately quantifying
antennary fucosylation in TPNG.
MALDI-FT-ICR-MS is not widely available. Therefore, we
also demonstrated that the assay can be measured with
a somewhat more widespread MALDI-TOF-MS instrument
(Supplementary Figure S28). In total, 58 glycans could be
relatively quantitated of which 15 were antennary fucosylated
glycans with a total abundance of 7.3% ± 0.7% using
MALDI-TOF-MS (Supplementary Table S8). In contrast, 19
antennary fucosylation glycans out of 70 glycans in total
were quantified with a total abundance of 11.8% ± 0.9%
using MALDI-FT-ICR-MS (Supplementary Table S7). Thus,
fewer antennary fucosylated glycans were quantified with
MALDI-TOF-MS due to the expectedly lower sensitivity of the
instrument. Furthermore, the differences in quantified antennary
fucosylation between the instruments can be accounted for
by the different efficiencies of ionization and ion transfer
to the detector over the m/z range; the MALDI-FT-ICR-MS
having been more efficiently tuned for good sensitivity in the
high mass range. Consistent with the overall trend, the three
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FIGURE 6 | Intermediate precision of sample preparation for assay and MALDI-FT-ICR-MS measurements of antennary fucosylated glycans in human TPNG. (A) The
mean relative abundances of the 19 quantified antennary fucosylated glycans are shown with the error bars representing standard deviation (n = 9). (B) The relative
standard deviations of the three most abundant antennary fucosylated glycans are shown. The description of the glycan cartoons are as described in Figure 1. [H =
hexose, N = N-acetylhexosamine, F = deoxyhexose (fucose), Am = amidated N-acetylneuraminic acid (α2,3-linked), E = ethyl esterified N-acetylneuraminic acid
(α2,6-linked)].
most abundant antennary fucosylated glycans also show lower
(or equal) values in the MALDI-TOF-MS, H6N5F1Am1E2,
H5N4F1Am1E1, and H6N5F1Am2E1, contributing to 3.9% ±
0.4%, 0.81%± 0.07% and 0.41%± 0.05% of the total abundance,
respectively (Supplementary Figure S28B). The abundance of
H6N5F1Am1E2 is consistent with previous MALDI-TOF-MS
analysis of TPNG (Reiding et al., 2014; Bladergroen et al.,
2015). The median of intermediate precisions for the 15
quantitated antennary fucosylated glycans is 12.5% (10.6–
13.6% interquartile range; Supplementary Figure S29), which is
virtually identical to our MALDI-FT-ICR-MS measurements of
the 19 antennary fucosylated glycans. The intermediate precision
of all N-glycans quantitated by MALDI-TOF-MS is shown in
Supplementary Figure S30. Thus, the assay measured on either
instrument can be used for detailed quantitation of antennary
fucosylation in human TPNG.
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Quantitation of Antennary Fucosylation in
Colorectal Cancer Patient Samples
To demonstrate the applicability of the developed antennary
fucose assay and especially its ability to reveal clinically
relevant markers of antennary fucosylation, total serum N-
glycome (TSNG) samples were analyzed from colorectal cancer
patients pre and post tumor resection. This is of specific
interest, as colorectal cancer has been associated with an
increase in antennary fucosylation and a decrease in core
fucosylation, next to an increase in N-glycan antennarity and
sialylation (de Vroome et al., 2018; Doherty et al., 2018).
Previously, TSNG has been analyzed by MALDI-TOF-MS on
sample pairs (pre-operative vs. post-operative) of 61 colorectal
cancer patients from the same cohort (de Vroome et al.,
2018). The derived traits that were a proxy for antennary
fucosylation on N-glycans are especially relevant to our study.
Multifucosylation on triantennary glycans and α2,3-sialylation
per antenna in fucosylated triantennary glycans were significantly
FIGURE 7 | Alteration in features related to antennary fucosylated glycans for colorectal cancer patient samples. Derived traits for glycans were calculated to evaluate
antennary fucosylation changes between the 14 pairs of pre-operative (Pre) vs. post-operative (Post) colorectal cancer patient samples. The patient samples were
measured with the antennary fucose assay (MALDI-FT-ICR-MS readout). Significant changes were observed for antennary fucosylation in complex N-glycans (CFan),
antennary fucosylation in triantennary glycans (A3Fan), antennary fucosylation in tetraantennary glycans (A4Fan), α2,3-sialylation per antenna of total antennary
fucosylated glycans (CFanAm), α2,3-sialylation per antenna of diantennary antennary fucosylated glycans (A2FanAm), sialyl-Lewis x abundance (relative area%) in
TPNG (SLex), Lewis x abundance in TPNG (Lex) and the ratio of sialyl-Lewis x to Lewis x abundances in TPNG (SLex / Lex). No significant changes were observed
for antennary fucosylation in diantennary glycans (A2Fan), α2,3-sialylation per antenna of triantennary antennary fucosylated glycans (A3FanAm) and α2,3-sialylation
per antenna of tetraantennary antennary fucosylated glycans (A4FanAm). The p-values shown are from a Wilcoxon matched-pairs signed-rank test with confidence
level taken as 95%. Multiple-testing correction was performed using a false discovery rate of 1% calculated with the Benjamini and Hochberg method. The p-values <
0.0073 are considered significant and are represented with an asterisk (*).
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lowered in the post-operative patient samples as compared
to pre-operative samples (de Vroome et al., 2018). The latter
derived trait was used as a proxy for sialyl-Lewis x epitopes
in TSNG. These changes were thought to be associated
with the recovery of the patients since values were closer
to healthy controls in the post-operative than in the pre-
operative samples.
The feasibility to analyze clinically relevant markers of
antennary fucosylation with our assay was demonstrated
on sample pairs (pre-operative vs. post-operative) of
14 colorectal cancer patients. Glycosylation changes in
colorectal cancer patient samples are shown in Figure 7
and Supplementary Figure S31. Details on features and their
calculations are shown in Supplementary Table S4. In line with
previous findings, we were able to show that post-operative
patient samples had a significantly lower total antennary
fucosylation on total complex N-glycans (CFan) as compared
to pre-operative samples (Figure 7). Unlike previously, no
significant differences were observed in α2,3-sialylation
per antenna of antennary fucosylated triantennary glycans
(A3FanAm), but rather a significantly lowered α2,3-sialylation
per antenna of antennary fucosylation diantennary glycans
(A2FanAm) in post-operative patient samples as compared to
pre-operative samples (Figure 7). Since we used only a quarter of
the samples, compared to the previous study, missing statistical
power provides a simple explanation for missing the sialylation
effect on fucosylated triantennary glycans. However, when we
focused on the quantitation of sialyl-Lewis x epitopes, it was
possible to reproduce the finding. We are able to calculate
highly specific derived traits based on antennary fucosylated
glycans structures, allowing us to study more specific glycan
features. For example, assuming α2,6-sialylated antennae are
not fucosylated, there is no preference for fucosylation of α2,3-
sialylated or asialylated antennae and multiple fucoses are on
different arms, the relative abundances of sialyl-Lewis x can be
calculated. This is indeed lowered in the post-operative samples
(Figure 7). The discovery of a novel association with A2FanAm
is also easily explained by the increased specificity of our assay.
The trait is largely composed of compositions representing
a mixture of core and antennary fucose isomers before core
defucosylation. Hence, in a regular TPNG/TSNG MALDI-MS
analysis unrelated variations in core fucosylation would interfere
with the detection of changes in antennary fucosylation of
diantennary glycans.
The changes in CFan are mainly contributed by the
triantennary glycans (A3Fan) and tetraantennary glycans
(A4Fan) rather than the diantennary glycans (A2Fan) and
bisecting diantennary glycans (A2BFan) (A2BFan shown in
Supplementary Figure S31). We did not observe a change
in A2Fan and A2BFan. Without core defucosylation,
these traits would largely measure core fucosylation
(Supplementary Figure S4). Furthermore, we also observed a
significantly lowered multiantennary fucosylation (CFm_an)
in post-operative patient samples as compared to pre-
operative samples (Supplementary Figure S31). Finally, we
also approximated the abundance of glycans having Lex
or sialyl-Lewis x epitopes in TPNG. sialyl-Lewis x / Lewis
x ratio was significantly lowered in post-operative patient
samples as compared to pre-operative samples. This change
was mainly contributed by a decreased abundance of sialyl-
Lewis x in post-operative samples, although the Lewis x
abundance was also lowered. This may be associated with
a decreased inflammatory state of the recovering patient
(Brinkman-van der Linden et al., 1998; Higai et al., 2005).
All studied features, except for Lewis x (p = 0.0513),
were replicated for the MALDI-TOF-MS measurements of
the samples (Supplementary Figure S32). Thus, MALDI-TOF-
MS measurements are sufficient to detect many of the
clinical changes.
CONCLUSION
We developed an assay for the relative quantitation of antennary
fucosylation and approximation of Lewis x and sialyl-Lewis
x abundances in TPNG, based on high-throughput MALDI-
MS analysis. This assay is compatible with high sensitivity and
ultrahigh-resolution MALDI-FT-ICR-MS or with MALDI-TOF-
MS. In total, 19 antennary fucosylated glycans were relatively
quantified with precision and accuracy expectable of a MALDI-
MS approach. Furthermore, the assay was applied to measuring
biomedically relevant changes in antennary fucosylation in
colorectal cancer patients pre vs. post tumor resection. Next to
previous findings that could be repeated, despite the reduced
sample size, the increased specificity enabled the discovery of
novel associations. Additionally, we were able to investigate
more specialized features based on antennary fucosylation
which would not be possible with regular TPNG analysis. The
next steps would include further automatization of the assay
and perform a high throughput analysis on a large set of
patient samples.
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